Last updated: 10/26/2020 16:00:06
Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) vaccine (GSK580299) in healthy female subjects 10-25 years of age.
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ HPV vaccine GSK580299 in healthy female subjects aged 10-25 years.
Trial description: Cervical cancer is the second most common cancer among women worldwide. Approximately 500 000 new cases are reported each year worldwide, from which 83% occur in developing countries. The incidence of cervical cancer varies depending on the region of the world. Africa has some of the highest age-standardized incidence and mortality rates in the world (Eastern Africa 42.7 and 34.6 per 100 000; Southern Africa 38.2 and 22.6 per 100 000; Western Africa 29.3 and 23.8 per 100 000; Middle Africa 28.0 and 23.0 per 100 000).As in the majority of developing countries, organization of cervical cancer screening programs in Africa is difficult to manage, especially in rural areas. HPV prophylactic vaccination could therefore clearly and efficiently decrease the incidence of cervical cancer. The current study is designed to assess the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 AS04 vaccine in female subjects enrolled from multiple countries in Africa.Ideally, HPV vaccination should be performed before onset of sexual activity, since studies have shown that acquisition of high-risk HPV occurs soon after sexual debut. This study will therefore be performed in subjects aged 10 to 25 years of age.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of seroconverted subjects for anti-human papillomavirus (HPV)-16 and 18 antibodies
Timeframe: At Month 7
Geometric Mean Titers (GMTs) of anti-HPV-16 and anti-HPV-18 antibodies
Timeframe: At Month 7
Secondary outcomes:
Number of seroconverted subjects for anti-HPV-16 and anti-HPV-18 antibodies
Timeframe: At Month 2 and Month 12
GMTs for anti-HPV-16 and anti-HPV-18 antibodies
Timeframe: At Month 2 and Month 12
Number of subjects with any and Grade 3 solicited local symptoms
Timeframe: Within 7 days (Day 0-6) after each dose and across doses
Number of subjects with any, Grade 3 and related solicited general symptoms
Timeframe: Within 7 days (Day 0-6) after each dose and across doses
Number of subjects with any, grade 3 and related unsolicited adverse events (AEs)
Timeframe: Within 30 days (Day 0-29) after any vaccination
Number of subjects with NOCDs and other MSCs
Timeframe: From Day 0 up to Month 7 and from Month 7 up to Month 12
Number of subjects with serious adverse events (SAEs)
Timeframe: From Day 0 up to Month 7 and from Month 7 up to Month 12
Number of subjects with pregnancies and their outcomes
Timeframe: From Day 0 up to Month 12
Number of Senegalese subjects with clinically relevant abnormalities in parameters assessed
Timeframe: At Month 7
Number of Tanzanian subjects with clinically relevant abnormalities in parameters assessed
Timeframe: At Month 7
Number of Senegalese subjects with clinically relevant abnormalities in parameters assessed
Timeframe: At Month 12
Number of Tanzanian subjects with clinically relevant abnormalities in parameters assessed
Timeframe: At Month 12
Interventions:
Enrollment:
676
Primary completion date:
2010-25-02
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Kiviat N et al. Immunisation of African pre-teen/adolescent girls and young women with the HPV-16/18 AS04-adjuvanted vaccine. Abstract presented at South African Society of Obstetricians and Gynaecologists - O & G Update 2011. Pretoria, South Africa, 5-7 May 2011.
Sow PS et al. (2012) Safety and immunogenicity of Human Papillomavirus-16/18 AS04-adjuvanted vaccine: A randomized trial in 10-25-year-old HIV-seronegative African girls and young women. J Infect Dis. doi: 10.1093/infdis/jis619. [Epub ahead of print].
Sow PS. et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in African preteen/adolescent girls and young women. Abstract presented at the African Organisation for Research and Training in Cancer (AORTIC). Cairo, Egypt, November 30 – December 3, 2011.
Watson-Jones D et al. (2013) High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects. Sex Transm Infect. doi:10.1136/sextrans-2012-050685. [Epub ahead of print].
Medical condition
Human Papillomavirus (HPV) infection
Product
SB580299
Collaborators
Not applicable
Study date(s)
October 2007 to July 2010
Type
Interventional
Phase
3
Participation criteria
Sex
Female
Age
10 - 25 years
Accepts healthy volunteers
Yes
- Subjects who the investigator believes that they and/or their parents/legally acceptable representative can and will comply with the requirements of the protocol should be enrolled in the study.
- A female between, and including, 10 and 25 years of age at the time of the first vaccination.
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 12).
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose or planned administration during the study period.
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects who the investigator believes that they and/or their parents/legally acceptable representative can and will comply with the requirements of the protocol should be enrolled in the study.
- A female between, and including, 10 and 25 years of age at the time of the first vaccination.
- Written or oral, signed or thumb printed or witnessed informed consent obtained from the subject prior to enrolment. For subjects below legal age of consent, written or oral, signed or thumb printed or witnessed informed consent obtained from the subject's parent or legally acceptable representative. In addition, a written or oral, signed or thumb printed and witnessed informed assent must be obtained from the subject.
- Free of obvious health problems as established by medical history, clinical examination and laboratory testing before entering into the study.
- Subjects must have a negative urine pregnancy test at the screening visit and at Visit 1 (Day 0).
- Subjects must be seronegative for human immunodeficiency virus (HIV) at the screening visit.
- Subjects must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series. Subjects who reach menarche during the study and therefore are of childbearing potential must agree to follow the same precautions.
- Subjects must have had no more than 6 sexual partners prior to enrolment.
- Subjects must be willing to undergo HIV voluntary counselling and testing and must be willing to be informed of their HIV status. Subjects below legal age of consent must also be willing to have their parent or legally acceptable representative informed of their HIV status.
Exclusion criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 12).
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose or planned administration during the study period.
- Administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine. Enrolment will be deferred until the subject is outside of specified window.
- Planned administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after any dose of study vaccine.
- Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
- Previous administration of components of the investigational vaccine.
- Cancer or autoimmune disease under treatment.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection based on laboratory testing performed during the screening visit.
- Hypersensitivity to latex.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine/control.
- Acute disease at the time of enrolment.
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory testing performed at the screening visit.
- History of any neurologic disorders or seizures.
- Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- Pregnant or breastfeeding female.
- A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2010-25-02
Actual study completion date
2010-26-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website